Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lupus Treatment Advances Lag Behind Other Rheumatic Diseases

Larry Beresford  |  Issue: August 2016  |  August 11, 2016

Other strategies for B cell interventions target B cell surface receptors, soluble modulators that lead to B cell proliferation and differentiation, and B cell signaling mechanisms downstream of the B cell receptor, Dr. Dall’Era noted. Drugs recently under investigation for BAFF-blockade include blisibimod, tabalumab and atacicept, which is unique in that it targets both BAFF and APRIL (a proliferation-inducing ligand).

Evidence for the role of type 1 inter­ferons in SLE includes the fact that treatment with interferon-alpha leads to a lupus-like disease, risk polymorphisms for lupus are present in interferon-regulated genes, interferon signature is present in peripheral blood mononuclear cells and in tissues from lupus patients, and the level of expression of interferon-inducible genes correlates with disease activity. Drugs that have been studied include rontalizumab and sifalimumab, whose development have been discontinued; and anifrolumab, which is continuing in Phase III trials.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

More than 500 current clinical trials of lupus therapies point toward a bright future, increasing the likelihood of demonstrating efficacy of novel experimental agents. —Dr. Dall’Era

Advances in Treating Lupus Nephritis

A major manifestation of SLE, lupus nephritis, is also being targeted with new treatment strategies, Dr. Dall’Era reported. Conventional induction treatment involves high doses of glucocorticoids, along with such drugs as mycophenolate mofetil or cyclophosphamide. An emerging strategy is multi-target therapy, she said, “already standard of care in the treatment of patients who have undergone organ transplant.” One recent small trial demonstrated the efficacy of the combination of tacrolimus and mycophenolate mofetil when compared with intravenous cyclophosphamide for induction treatment of lupus nephritis. Another trial in progress is studying the combination of voclosporin (a next generation calcineurin inhibitor) in combination with mycophenolate mofetil.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Another active area of research involves novel ways to use rituximab for the treatment of lupus nephritis. The Rituxilup trial, with European and American collaborators, is assessing the use of rituximab instead of, rather than as add-on therapy to, oral steroids. Rituximab is being given in combination with two doses of intravenous steroids and followed by mycophenolate mofetil. In the CALIBRATE trial, patients with lupus nephritis are undergoing an induction regimen of rituximab and two doses of intravenous cyclophosphamide, followed by belimumab maintenance.


Larry Beresford is an Oakland, Calif.-based freelance medical journalist.

References

  1. Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343–1349.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:California Rheumatology Alliance 2016Lupuspatient careResearchRheumatic DiseaseSLETreatmentupdate

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    July 18, 2019

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    BAFF: A Fulcrum Between Resistance to Infection & Autoimmunity

    May 31, 2017

    New research has linked a TNFSF13B variant and B cell activating factor (BAFF), a common therapeutic target, with multiple sclerosis and systemic lupus erythematosus. The variant is a disease-risk allele associated with increased levels of soluble BAFF…

    Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences